Sage Therapeutics said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the ...

Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the ...

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild ...

Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results from its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for the treatment ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...

Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...

Sage Therapeutics does not plan further clinical development of its dalzanemdor drug candidate in Alzheimer's disease following its failure in a mid-stage study.

The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.

Sage said it will continue to test dalzanemdor as a treatment for Huntington's disease and expects to report its mid-stage ...

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...